



AROA BIOSURGERY HALF YEAR RESULTS WEBINAR

Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX, 'AROA' or the 'Company') is pleased to announce it will hold a webinar with CEO Brian Ward and CFO James Agnew on Tuesday November 29, 2022, at 11 am AEST, to discuss the Company's half year results.

Investors and interested parties can register to attend the webinar via the following link:

https://us02web.zoom.us/webinar/register/WN_1OvvlhH8TruQSaY0HEaHHw

Questions can be submitted prior to the webinar to shinsley@aroabio.com or during the webinar using the Q&A function on Zoom.

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

About Aroa Biosurgery:

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine forestomach. AROA has six patented product families selling in the US based on its AROA ECM technology, targeting chronic wounds, hernia, soft tissue and breast reconstruction. AROA's products have been used in more than 5.6 million procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio. AROA has regulatory approvals in 49 countries. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroabio.com/

Contacts

Investor

Simon Hinsley
Investor Relations
shinsley@aroabio.com
+ 61 401 809 653

Media

Australia
Matthew Wright
matt@nwrcommunications.com.au
+61 451 896 420

New Zealand
Sarah Tora
sarah.tora@aroabio.com
+64 21 531 043